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Superinduction of IL-6 synthesis in human peritoneal mesothelial cells
is related to the induction and stabilization of IL-6 mRNA. The initiation
of peritonitis is accompanied by a massive increase in intraperitoneal
levels of IL-6. The source of this cytokinc and the mechanism by which its
levels are increased so dramatically are unknown. We examined the
mechanism of IL-6 secretion by HPMC exposed to the milieu present in
the peritoneal cavity during the initiation of inflammation. Exposure of
HPMC to spent peritoneal dialysis effluent (PDE) or IL-113 resulted in a
time- and dose-dependent increase in IL-6 secretion. After 24 hours the
IL-6 release (pg4g cell protein) was increased from 5.0 0.8 in control
cells to 16.0 2.4 and to 83.8 17.4 in HPMC treated with PDE and
IL-lp (1000 pg/mI), respectively (N = 5, P < 0.05). If, however, PDE and
IL-113 were combined, then the secretion of IL-6 was synergistically
increased to 747.7 349.9 (P < 0.05 vs. expected additive value). The
same effect was evident when PDE was combined with TNFcs or mixed
with peritoneal macrophage conditioned medium. These changes were not
a reflection of HPMC proliferation as estimated by 3H-thymidine incor-
poration. The "superinduction" of IL-6 release was associated both with
the induction and stabilization of IL-6 mRNA. Competitive PCR demon-
strated that the amount of IL-6 mRNA (fM/jLg total RNA) was increased
from 0.35 0.13 in control cells to 11.66 3.89 and to 10.83 5.17 in
HPMC treated with PDE and IL-I j3 (100 pg/mI), respectively (N = 5, P <
0.05). The combination of PDE + IL-113 synergistically increased IL-6
mRNA levels to 56.33 8.79 (P < 0.05 vs. additive value). RNA stability
experiments using actinomycin D revealed that the half life of IL-fl mRNA
(hours) was increased from 2.8 hours in control cells to 6.7 and 9.4 in
HPMC exposed to PDE and IL-I 13, respectively. The combination of PDE
together with IL-1$ resulted in a prolonged stabilization of IL-6 mRNA
with levels remaining constant over the 12 hours of the experiment. These
data demonstrate that HPMC IL-fl synthesis can be synergistically ampli-
fied in the presence of peritoneal dialysis effluent and PM0-derived
cytokines. The results suggest that the peritoneal mesothelium may be
responsible for the dramatic rise in IL-6 levels seen during the initial
stages of CAPD peritonitis.
Continuous ambulatory peritoneal dialysis (CAPD) has become
an established form of therapy for patients with end-stage renal
insufficiency. The successful outcome of APD depends largely
on the long-term preservation of the peritoneal membrane as a
dialyzing organ. The integrity of the peritoneal membrane may,
however, be easily jeopardized by peritonitis, which still remains a
major complication in patients undergoing CAPD. In severe cases
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the consequence of repeated episodes of peritonitis may be
irreparable damage to the peritoneal membrane, loss of ultrafil-
tration, and treatment failure [1j.
Examination of intraperitoneal levels of inflammatory media-
tors prior to and during peritonitis have revealed that the intra-
peritoneal levels of prostaglandins (PGE7 and 6-keto-PGF1,) and
eytokines (IL-i, TNFa, IL-6, IL-8, and IFN-y) are significantly
elevated during acute phase of peritonitis and subsequently return
to basal values when the inflammatory process subsides [2—9].
Moreover, it has been demonstrated that this rise (specifically in
TNFcs levels) may even precede the occurrence of clinical signs of
infection [5, 101. Thus the specific time courses of cytokine
appearance in peritoneal dialysis effluent may identify different
stages of the intraperitoneal inflammatory response.
In 1990 Goldman et al [6] and then several other groups [7,
11—131 observed that the initiation of peritonitis in CAPD patients
was accompanied by a massive increase (100- to 10,000-fold) in
intraperitoneal levels of interleukin-6 (IL-6). The source of this
cytokine, its function within peritoneal cavity, and the mechanism
by which its levels increased so dramatically have not been fully
identified. The observation that the JL-6 dialysate/serum ratios in
peritonitis CAPD patients were much higher than could he
predicted on the basis of simple diffusion of IL-6 from circulation
to the peritoneal cavity provided evidence that IL-6 might be
produced intraperitoneally [14]. This focused attention on perito-
neal macrophages (PM0), which are commonly viewed as the first
line of defence against invading microorganisms and as such are
believed to be a major source of inflammatory mediators initiating
the inflammatory response. It has been demonstrated that PMØ
from infection-free CAPD patients release significant quantities
of eicosanoids and are capable of generating considerable
amounts of cytokines when challenged with S. epidermidis isolates
[15, 161.
More recently, however, increasing evidence suggests that there
is another likely candidate as a potent source of intraperitoneal
IL-6. The peritoneal mesothelium has been shown to act not only
as an inert lining of the peritoneal cavity, but also to possess the
capacity to produce cytokines. It has been demonstrated that
cultured human peritoneal mesothelial cells (HPMC) secrete
biologically active IL-6, and that the IL-6 synthesis can be
markedly augmented in response to pro-inflammatory cytokines
IL-113 and TNFcs as a result of specific induction of IL-6 mRNA
[17].
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In this study we aimed to characterize the mechanism of IL-6
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secretion by HPMC at both the protein and mRNA levels in the
milieu mimicking that of peritoneal inflammation. Our data
demonstrate that HPMC IL-6 synthesis can be synergistically
amplified in the environment consisting of spent peritoneal dia-
lysate and PM0-derived cytokines. This observation indicates that
the peritoneal mesothelium may be responsible for the dramatic
rise in IL-6 levels seen during the initial stages of peritonitis.
Methods
All chemicals, unless otherwise stated, were purchased from the
Sigma Chemical Company (Poole, Dorset, UK). Recombinant
human IL-1j3 was obtained from Advanced Protein Products Ltd
(Brierley Hill, UK). Its biological activity (expressed as ED50) was
below 0.1 ng/ml as determined by the uptake of thymidine by
murine C3H/HeJ thymocytes. Human TNFs was obtained from
BASF AG (Ludwigshafen, Germany). Its specific activity was 8 X
i0 U/mg protein as assessed in a 48 hour L929 bioassay in the
absence of actinomycin D. Human recombinant IL-I receptor
antagonist (IL-Ira) was kindly provided by Dr. P. Scholtz (Scher-
ing AG, Berlin, Germany). All cytokine preparations were
batched and stored at —70°C and freshly thawed for each
experiment. Endotoxin contamination of recombinant material
was below 0.7 pg/sg protein as assessed by limulus amoebocyte
lysate assay (Kabi Vitrum, Stockholm, Sweden). All tissue culture
flasks and multi-well plates were obtained from Falcon (Becton-
Dickinson UK Ltd, Oxford, UK).
Isolation and culture of human peritoneal mesothelial cells
Human peritoneal mesothelial cells (HPMC) were obtained
from the omental tissue of consenting non-uremic patients under-
going elective abdominal surgery. The cells were isolated and
characterized essentially as described previously [18]. The identity
of mesothelial cells was confirmed by their uniform cobblestone
appearance at confluence, by the presence of surface microvilli,
and by the uniform positive staining for cytokeratins 8 and 18. The
endothelial origin of the cells cultured was excluded by the lack of
staining for the factor VIJI-related antigen and by the absence of
endothelin-1 secretion [19]. The presence of contaminating mac-
rophages was excluded following assessment of Fe receptor
expression (using a red cell rosetting assay that was negative in all
mesothelial cell cultures examined). Cells were maintained in the
Earle's buffered M 199 culture medium (Sera Lab/JRH Bio-
sciences Ltd, Crawley, UK) supplemented with penicillin (100
U/mI), streptomycin (100 sg/ml), L-glutamine (2 mM) (Gibco
BRL, Life Technologies Ltd, Paisley, UK), transferriri (5 JLg/ml),
insulin (5 sg/ml), hydrocortisone (0.4 jtg/ml) (all from Sigma) and
10% vol/vol fetal calf serum (FCS) (Sera Lab Ltd). HPMC
cultures were maintained at 37°C in a humidified 5% CO2
atmosphere.
Cells were passaged using a trypsin:EDTA solution (0.125%
wt/vol:0.01% wt/vol). All data presented are from experiments
performed with cells from the second passage that had previously
been growth arrested as described below. Cells used were from
the second passage and not later to minimize the number of
senescent cells that appeared from the third passage onwards [17,
18].
Establishment of growth anested HPMC
After HPMC reached confluence in multi-well plates, the 10%
FCS-containing medium was removed and cells were washed
three times with the culture medium containing 0.1% vol/vol FCS
(rest medium). Then HPMC were incubated in the rest medium
for 48 hours prior to stimulation. Previous experiments had
demonstrated that at this time point the cells were maintained in
a viable (as assessed by the lack of LDH release and constant
cellular ATP levels) but non-proliferative state (data not shown).
Under these conditions the cells could be maintained for up to 96
hours without any significant loss of viability [17].
Peritoneal dialysis effluent
The samples of peritoneal dialysis effluent (PDE) were ob-
tained from consenting non-infected CAPD patients (N = 9)
using the following technique. Four hours after intraperitoneal
infusion of 2.0 liters of fresh peritoneal dialysis solution (Baxter
Healthcare Ltd, Thetford, Norfolk, UK), containing 1.36% wt/vol
glucose and no other additives, the spent dialysate was drained
into the dialysis bag. Then the effluent was transferred to sterile
tubes, immediately centrifuged (4000 X g for 30 mm) and filtered
through 0.2 jsm pore size filter (Minisart, Sartorius Ltd, Epsom,
UK) to remove any cellular material. Equal volumes of samples
from individual patients were pooled and stored in aliquots at
—70°C until required.
Peritoneal macrophage (PMØ) conditioned medium
PMØ were harvested from peritoneal dialysis effluent of infec-
tion-free CAPD patients as described in detail elsewhere [151.
More than 95% of the cells remaining adherent to the Petri dishes
(Becton-Dickinson UK Ltd) were consistently found to be PMØ
as assessed morphologically following staining with the Neat
Differential Haematology Stain (Guest Medical Ltd., Sevenoaks,
UK). Conditioned media were collected from PMØ cultures
following a three hour incubation in the culture medium alone
(PM0-CM) or from PMØ stimulated with a strain of Staphylo-
coccus epidermidis (S. epidermidis DM), isolated from the perito-
neal dialysis effluent of a CAPD patient with peritonitis (S.epi/
PMØ-CM), as previously described [16].
Induction of IL-6 production by HPMC
HPMC were grown to confluence in 24-well plates and growth
arrested as previously described. Then cells were washed three
times with the rest medium and incubated for 24 hours at 37°C
with either the control medium (containing 0.1% FCS) or pooled
PDE, both in the presence or absence of IL-113. In separate
experiments HPMC were exposed to the peritoneal macrophage
conditioned-media (PM0-CM or S.epiPMø-CM) combined with
either the control medium or PDE. In the inhibition studies
HPMC were pre-treated with the transcription inhibitor actino-
mycin D (Sigma) for 30 minutes at 37°C prior to stimulation.
At designated time intervals the HPMC supernatants were
removed, centrifuged at 12000 >< g and stored at —70°C until
assayed. The cells were washed twice with phosphate buffered
saline, pH 7.3 (PBS Dulbecco's; Gibco BRL, Life Technologies
Ltd, Paisley, UK) and solubilized with 0.1 N NaOI-I. Total cellular
protein was then analyzed by the modified Bradford method [201
using bovine serum albumin (Sigma) as the standard. Repeated
cell counts revealed that 1 jig of cellular protein was equivalent to
3.76 0.56 X i0 cells (N = 20). All data for JL-6 production are
expressed as pg/jig of cellular protein. In all experiments the PDE
(and the respective control medium) was supplemented with
heparin to a final concentration of 5 U/mI to avoid the clot
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Table 1.
F: 5'-GGAGCAATGATCTTGATC11T-3
R: 5 -TCCTGAGGTACGGGTCCTTCC-3'
F: 5'-TACATCCTCGACGGCATCTC-3'
R: 5'-GCTACAmGCCGAAGAGCC-3'
F: 5 '-TACATCCTCGACGGCATCTCGCCCCAGCCACCCATITGTA-3'
R: 5 '-GCTACATTTGCCGAAGAGCCGCTCCCTGCCCAVTTCTGTC-3'
formation. Incubation of HPMC with recombinant cytokines,
PDE or PM0-conditioned media for up to 48 hours did not
reduce cell viability as assessed by the LDH release (data not
shown).
IL-6 production measurements
The concentration of JL-6 in HPMC supernatants was mea-
sured using a specific sandwich-ELISA as previously described
[211. The specific release of IL-6 from HPMC was calculated
following the subtraction of background IL-6 levels detected in
either control medium, PDE, PM0-CM or S.epiPMø-CM from
those recorded in the postculture supernatants.
RNA isolation, reverse transcription (RT) and polymerase chain
reaction (FCR)
HPMC were grown to confluence in six-well plates and ren-
dered quiescent as previously described. Then cells were washed
three times with a rest medium and exposed to either the control
medium (containing 0.1% FCS) or PDE and incubated in the
presence or absence of 1L-l (100 pg/mi) for up to 24 hours. At
defined time periods total cellular RNA was extracted from
HPMC following lysis with 4 M guanidine isothiocyanate and
centrifugation through 5.7 M caesium chloride/0.1 vi EDTA
solution [221.
The total RNA was reverse transcribed into eDNA using the
random hexamers method as previously described [17, 23]. Briefly,
the reaction mixture contained 1 j.d random hexamers (100 jiM;
Pharmacia Biosystems Ltd, Milton Keynes, UK), 5 pd dNTPs (2.5
mM, Gibco BRL), 2 jil lOx PCR buffer (100 mvt Tris/HC1, 500 mM
KC1, 15 mvi MgCI2 and 0.01% wt/vol gelatin), 2 p.l dithiothreitol
(0.1 M, Gibco BRL), 1 jil RNasin ribonuclease inhibitor (Pro-
mega, Southampton, UK), 1 pJ M-MLV° Superscript reverse
transcriptase (200 units; Gibco BRL) and 1 jig of total RNA.
PCR amplification was performed in a total volume of 50 p.l (2
j.tl of reverse transcription product and 48 jil of master mix
containing 36.25 jii H20, 1.25 jrl 5-primer (20 jiM), 1.25 jil
3'-primer (20 jiM), 4 jil dNTPs, 5 j.d lOx PCR buffer and 0.25 j.tl
Taq polymerase (2.5 U, Amplitaq©, Perkin Elmer Ltd, Bea-
consfield, UK) using a Perkin Elmer 480 Thermocycler (Perkin
Elmer Cetus, Applied Biosystems Ltd, Warrington, UK). The
PCR protocol was as follows: first cycle —94°C for three minutes,
55°C for one minute, 72°C for one minute; second to 25th cycles
—94°C for 40 seconds, 55°C for one minute, 72°C for one minute.
The final cycle was 94°C for 40 seconds and 60°C for 10 minutes.
PCR was performed for 23 cycles for a-actin and 25 cycles for
IL-6. Preliminary experiments revealed that under these condi-
tions the PCR products were generated during the exponential
phase of amplification. One-tenth of the PCR reaction from both
test (IL-6) and control (a-actin) products were mixed and sepa-
Time, hours
Fig. 1. Time course of JL-6 synthesis by HPMC in response to PDE and
IL-I/3 Growth arrested HPMC were exposed to control medium or PDE
in the presence or absence of IL-113 (100 pg/mI) for up to 48 hours. Data
represent the mean SEM of 7 experiments performed with cells from
separate donors. °A statistically significant difference in HPMC IL-6
release compared to the control. °°A statistically significant synergistic
difference in HPMC IL-6 release compared to the expected additive
values for TL-1 and PDE at the same time point. Symbols are: (A)
PDE+IL-1J3; () PDE; (•) IL-i/I; () control.
rated by flat bed electrophoresis in 3% wt/vol NuSieve GTG'
agarose gels (Flowgen Instruments Ltd, Sittingbourne, UK),
stained with ethidium bromide (1 jig/mI, Sigma), visualized using
UV transillumination, and photographed. The negatives were
scanned using the Model GS670 video densitometer (Bio-Rad
Laboratories Ltd, Hemel Hempstead, UK) and the density of the
bands compared to those of the housekeeping gene using Molec-
ular Analyst° 2.0 software (Bio-Rad Laboratories, Inc., Hercules,
CA, USA).
Competitive PCR
Competitive PCR was performed using the PCR MIMIC'
Construction Kit (Clontech Laboratories Ltd, Cambridge Bio-
science, Cambridge, UK). The competitive DNA standard was
synthesized by amplification of the BamH I/EcoRl fragment of
v-erbB DNA using composite IL-6 primers. Both the primary PCR
amplification with IL-6 composite primers and the secondary PCR
amplification with IL-6 specific primers were performed for 30
cycles as follows: 94°C for 45 seconds, 60°C for 45 seconds, 72°C
for 90 seconds. The IL-6 MIMIC DNA obtained was purified with
a-actin
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[23]
[24]
*
**
*
**
*
**q)
Q)
C.)
0
Cu
ci)
a)
(0
-J
350 -
300 -
250 -
200 -
150 -
100
50
01
*
*
**
0 6
*
12 18 24 30 36 42 48
0
Control 0.1 1 101001000 PDE 0.1 1 10 100 1000
lL-lp, pg/mi PDE + IL-1f, pg/mi
B
150
*
**
125 1
2
CI.
100
C,
75 I
'if 1
50 * **a) * ** _
**
25 * *
0 iaapiIitIIIIiII
Control 0.1 1 101001000 PDE 0.1 1 10 100 1000
TNFa, pg/mi PDE + TNFaI pg/mi
1000
A
1200 ***
800
600
*
400
**
200 *
*
*
*
**
*
**
Witowski et a!: Superinduction of peritoneal IL-6 synthesis 1215
Fig. 2. A. Dose effect of IL-1/3 on JL-ó
generation by HPMC exposed to PDE. Growth
arrested HPMC were exposed to control
medium or PDE in the presence of increasing
doses of JL-l (0.1 to 1000 pg/mI) for 24 hours.
Data represent the mean SCM IL-6 release
from 6 experiments with HPMC isolated from
different omental specimens. *A statistically
significant difference in HPMC IL-6 release
compared to the control. * *A statistically
significant synergistic difference compared to
the expected additive values for PDE and IL-lp
at the same dose (composite bars). Symbols
are: () control; (13::) IL-1[3; () PDE; (•) IL-
1+PDE. B. Dose effect of TNFa on IL-6
generation by HPMC exposed to PDE. Growth
arrested HPMC were exposed to control
medium or PDE in the presence of increasing
doses of TNFs (0.1 to 1000 pg/mI) for 24
hours. Data represent the mean SCM IL-6
release from 6 experiments with HPMC
isolated from different omental specimens. *A
statistically significant difference in HPMC IL-6
release compared to the control. **A
statistically significant synergistic difference
compared to the expected additive values for
PDE and TNFo at the same dose (composite
bars). Symbols are: (LI) control; (El) TNFo; ()
PDE; (•) TNFa+PDE.
Wizard" PCR Preps DNA Purification System (Promega) accord-
ing to the manufacturer's protocol. The quantity of the purified
IL-6 MIMIC product was determined by spectrophotometry at
260 nm. Equal amounts of target eDNA derived from experimen-
tal RNA were PCR-amplified in the presence of twofold serial
dilutions of the IL-6 MIMIC according to the normal protocol for
IL-6 specific primers. The PCR products were resolved on the
agarose gels and the optical density of the bands was measured as
described previously. Then the ratio of the IL-6 target to the IL-6
MIMIC products was calculated and graphed as a function of the
IL-6 MIMIC concentration. From the standard curve generated in
this manner the initial amount of IL-6 target eDNA was deter-
mined by extrapolating from the point where the amounts of the
experimental eDNA and the MIMIC eDNA reached equivalence.
After the correction for the difference in size between the IL-6
target and the IL-6 MIMIC products the concentration of mRNA
in the original sample was estimated. A representative IL-6-PCR-
MIMIC standard curve for a single HPMC extract of mRNA is
shown in Figure 8.
Oligonucleotide synthesis
The IL-6 specific oligonucleotide amplification primers and the
composite primers for IL-6 MIMIC were synthesized by Genosys
Biotechnologies Ltd. (Cambridge, UK). The a-actin specific prim-
ers were obtained from Cruachem Ltd. (Glasgow, UK). The
primer sequences are in Table 1.
The stability of IL-6 rnRNA in IIPMC
The inherent stability of IL-6 mRNA in HPMC was assessed by
measuring the rate of IL-fl mRNA degradation in cells exposed to
the transcription inhibitor actinomycin D. Briefly, growth arrested
HPMC were stimulated with either control medium or PDE in the
presence or absence of IL-113 (100 pg/mI) for six hours at 37°C and
then pulsed with actinomycin D (0.5 jig/mI). At defined times up
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to 12 hours after the addition of actinomycin D the total HPMC
RNA was extracted, reverse transcribed and PCR amplified as
described above. Preliminary experiments revealed that HPMC
could be maintained in the presence of 0.5 jig/ml of actinomycin
D for up to 12 hours without significant loss of cell viability as
assessed by the level of cellular ATP (data not shown).
Effect of interleukin-1 receptor antagonist
In separate experiments growth arrested HPMC were co-
incubated with PDE and/or IL-1/3 in the presence of increasing
concentrations of IL-ira (0.1 to 1000 ng/ml). After 24 hours of
exposure the supernatants were assayed for IL-6 and the data
normalized for cellular protein content.
Effect of cycloheximide
Growth arrested HPMC were pre-treated with 10 g/ml of
cycloheximide (Aldrich Chemical Company, Gillingham, Dorset,
UK) for two hours at 37°C and then stimulated with PDE in the
presence or absence of IL-lp (100 pg/mI). After six hours of
exposure the total HPMC RNA was extracted, reverse transcribed
and PCR amplified as described above.
HPMC proliferation
Proliferation of HPMC in response to PDE was measured by
[3H]-thymidine incorporation assay. Cells were plated onto 96-
well plates at a density of 1.25 X i0 cells/well, cultured for 24
hours and then growth arrested as previously described. After that
subconfluent HPMC were exposed to PDE, pulsed with [3H1-
thymidine (as [methyl-3H]-thymidine; 2.5 pCi/ml; specific act. 82
Ci/mM; Amersham international plc, Aylesbury, UK) and incu-
bated in the presence or absence of IL-1/3 (1000 pg/mI) for 48
hours at 37°C. At the end of the exposure the labeling fluids were
removed and cells were washed twice with PBS and precipitated
with 10% wt/vol trichioroacetic acid. The precipitate was dissolved
in 0.1 N NaOH and the released radioactivity was measured in a
beta liquid scintillation counter (LKB Wallac, Turku, Finland).
Statistical analysis
All data were derived from experiments with HPMC prepared
from at least five separate donors. All statistical analyses were
performed using the Wilcoxon matched-pairs signed ranks test for
non-parametric data (Statview° SE; Abacus Concepts Inc.,
Berkeley, CA, USA) with a P value of less than 0.05 being
considered as significant. All data are presented as mean (± SEM).
Results
Induction of HPMC IL-6 production
Incubation of growth arrested HPMC with PDE resulted in a
time-dependent increase in IL-6 generation (Fig. 1). The time
course and the magnitude of the IL-6 release was comparable to
that induced by 100 pg/mI lL-13. In each case the secretion of IL-6
became significant above the control level after six hours and
reached a plateau by 24 hours. The combination of PDE together
with IL-if3, however, induced an IL-6 production above the levels
generated by each stimulus alone, and significantly above the
predicted additive value. This synergistic increase in the HPMC
IL-6 synthesis was first discernible at six hours, followed by large
increments over the next i8 hours and a plateau by 24 hours.
Repeated measurements over the whole study revealed that in
HPMC from different donors the increase in 24-hour IL-6 release
in response to a combination of PDE and 100 pg/mI IL-1f3 ranged
from 1.1- to 27.2-fold above expected additive levels (median
value 3.0-fold, N = 40).
The synergistic effect of the combined PDE and IL-lp stimu-
lation was dependent on the dose of IL-1/3 (Fig. 2A). It became
significant above additive values when PDE was combined with I
pg/ml IL-113 and maximal synergy was obtained at the highest
IL-1f3 dose tested (1000 pg/mI) when the 24-hour HPMC IL-6
secretion was 747.74 349.93 pg/.tg cell protein compared to the
additive value of 99.81 19.16 pg/jig cell protein (N = 6, z =
2.201, P < 0.027). The same effect was evident when IL-113 was
replaced with TNFa, although the degree of stimulation was much
less pronounced (Fig. 2B). A 24-hour exposure of HPMC to 1000
30
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Fig. 3. Dose effect of PDE on the capacity of
HPMC to release IL-6. Growth arrested HPMC
were exposed to increasing dilutions of PDE in
the presence or absence of IL-1j3 (100 pg/mI)
for 24 hours. Data represent the mean (
SEM) IL-6 release from 6 experiments with
HPMC from separate donors. *A statistically
significant difference in HPMC IL-6 release
compared to the control. * °A statistically
significant synergistic difference compared to
the expected additive values for IL-lp and
equivalent dilution of PDE (composite bars).
Symbols are: () control; (LI) PDE; () IL-1f3;
(U) PDE+IL-1j3.
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Fig. 4. Effect of macrophage-conditioned media and PDE on HPMC IL-6
synthesis. IL-6 generation by HPMC was measured following a 24-hour
exposure to PM0-CM or S. Epi PM0-CM mixed (1:5) with either control
medium or PDE. Data represent the mean SCM IL-6 release from 6
experiments with cells prepared from separate omental specimens. Sym-
bols are: (LI) control; (LI) PDE; () macrophage-CM; (U) PDE +
macrophage-CM. *A statistically significant difference in HPMC IL-6
release compared to the control. **A statistically significant synergistic
difference in HPMC IL-6 release compared to the expected additive
values for macrophage supernatants and PDE (composite bars).
pg/mi TNFa resulted in the IL-6 release of 15.17 3.31 pg/j.tg cell
protein (N = 6, z = 2.201, P < 0.027). The same dose of TNFa
applied together with PDE generated the IL-6 secretion of
98.12 24.33 pg/jig cell protein compared to the expected
additivevalue of 31.88 2.96 pg/jig cell protein (N= 6,z = 2.201,
P < 0.027).
The synergistic effect of the PDE and IL-1f3 combination was
also related to the PDE concentration (Fig. 3). Progressive
dilutions of the PDE reduced its capacity to stimulate HPMC IL-6
secretion. The potential of the PDE to superinduce IL-6 synthesis
in the presence IL-113, however, still occurred at dilutions between
1:2 and 1:5.
Induction of HPMC IL-6 by PMØ conditioned medium
The mean concentrations of IL-6 in undiluted pooled perito-
neal macrophage-conditioned medium (PM0-CM or S.epi PM0-
CM) were 72 and 161 pg/ml, respectively. These values were
subtracted from those detected in the HPMC supernatants to
assess specific release of mesothelial cell IL-6.
Exposure of HPMC to the peritoneal macrophage-conditioned
medium obtained either from control cultures (PMØ-CM) or
following the stimulation with S.epidermidis (S.epiPMø-CM) re-
sulted in a time- and dose-dependent stimulation of HPMC IL-6
secretion. At equivalent dilutions a 24-hour IL-6 release triggered
by S.epiPMø-CM always exceeded that induced by PM0-CM. At
the optimal dilution (1:5) the recorded IL-6 levels were 108.60
36.20 and 137.93 50,38 pg/jig cell protein for PM0-CM and
S.epiPMø-CM, respectively, (N = 6, z = 2.201, P < 0.027 vs.
control: 13.95 4,30 pg/jig cell protein). The similar pattern of
IL-6 secretion was detected when HPMC were exposed to PM0-
conditioned media mixed with PDE. In this case, however, the
degree of stimulation was significantly higher when compared to
HPMC treated with equivalent dilutions of PM0-CM in control
Actinomycin-D, jig/mi
Fig. 5. Actinomycin D inhibition of JL-6 release from HPMC exposed to
PDE and IL -1 13 Growth arrested HPMC were pre-treated with increasing
concentrations of actinomycin D for 30 minutes and then exposed to
control medium or PDE in the presence or absence of IL-1f3 (100 pg/mI)
for 24 hours. Data presented are the mean SEM of 5 experiments with
HPMC isolated from different omental specimens. *A statistically signif-
icant difference compared to untreated controls. Symbols are: (El) control;
(L:) IL-113; () PDE; (U) PDE+IL-1f3.
medium (Fig. 4). At the 1:5 dilution with PDE the levels of
HPMC-derived IL-6 were 259.59 89.23 and 400.59 88.94
pg/jig cell protein for PM0-CM and S.epiPMø-CM, respectively
(N = 6, z = 2.201, P < 0.027 vs. PDE alone: 55.73 23.03 pg/jig
cell protein). These levels were significantly above the calculated
sum of individual effects of respective PMØ supernatants and
spent dialysate.
Actinomycin D inhibition
Pre-exposure of HPMC to actinomycin D for 30 minutes at
37°C resulted in a dose-dependent inhibition of both PDE- and
IL-1j3-stimulated IL-6 release (Fig. 5). The maximal inhibition
was obtained with the highest dose tested (5 jig/mI) when the IL-6
generation was reduced by means of 83.4 6.9%, 92.0 4.5%,
and 97.9 1.0% for HPMC exposed to IL-1/3, PDE, and a
combination of IL-1f3 with PDE, respectively (N = 5, z 2.023,
P < 0.05 for all). Under the same conditions the constitutive IL-6
release was decreased by 94.3 4.8% (N = 5, z 2.023, P <
0.05).
Effect of interleukin-1 receptor antagonist
In HPMC treated with either control medium or PDE, both in
the presence or absence of IL-1j3 (100 pg/mI), the simultaneous
addition of IL-ira resulted in a dose-dependent reduction in the
HPMC IL-6 generation (Fig. 6). Following a 24-hour co-incuba-
tion with the highest concentration of IL-ira added (1000 ng/ml)
HPMC IL-6 synthesis was reduced by means of 85.0 9.4% and
81.8 10.3% in control cells and HPMC exposed to PDE,
respectively (N = 5, z = 2.023, P < 0.05 for both). Under the same
conditions the production of IL-6 was reduced by 92.7 5.7% and
81.9 14.5% in cells treated with IL-1/3 and a combination of
PDE+IL-lp, respectively (N = 5, z = 2.023, P < 0.05 for both).
*800
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0 0.1 1 10 100 1000
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*
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PCR analysis of HPMC IL-6 gene expression
For all mesothelial cell lines examined, the PCR amplification
of the reverse transcribed HPMC RNA, using specific IL-6
primers, produced single band IL-6 transcripts of 465 base pairs.
The IL-6 mRNA expression was assessed by comparison with the
204 base pair transcripts of the cs-actin housekeeping gene from
the same samples. Incubation of HPMC in the presence of either
PDE or IL-1/3 (100 pg/mI) resulted in an increased expression of
IL-6 mRNA as compared to unstimulated controls (Fig. 7). The
combination of PDE and IL-1/3 generated a prolonged increase in
the expression of IL-6 mRNA and above the levels recorded in
response to PDE or IL-1/3 alone. The maximal IL-6 mRNA
expression was observed 4 to 6 hours after the addition of IL-1/3
and/or PDE.
Competitive PCR
The conventional PCR amplification with the use of an endog-
enous internal standard (a-actin) gives only an estimate of relative
changes in mRNA expression. We therefore developed a semi-
quantitative competitive MIMIC-PCR to determine changes in
IL-6 mRNA abundance more precisely (Fig. 8). The coefficient of
variation in these assays varied between 62% to 107% depending
on stimulation (N = 20 determinations).
After six hours of incubation the amount of IL-6 mRNA (fM//kg
of total cellular RNA) was increased from 0.35 0.13 in control
cells to 10.83 5.17 in HPMC treated with IL-i [3 (100 pg/mI) and
to 11.66 3.89 in HPMC exposed to PDE (N = 5, z = 2.023, P <
0.05 for both; Fig. 9). Combined stimulation of HPMC with PDE
and IL-1/3 resulted in the IL-6 mRNA generation of 56.33 8.79
fM//kg of total cellular RNA (N = 5, z 2.023, P < 0.05); this level
was significantly above the calculated sum of individual stimula-
tory capacities of PDE and IL-1!3 (250.5 39.1% of the predicted
additive value; N = 5, z = 2.023, P < 0.05).
Stability of IL-6 mRNA in HPMC
The stability of the PDE- and cytokine-induced HPMC IL-6
mRNA was assessed in actinomycin D chase experiments. These
experiments revealed that in cells treated singly with PDE or
lL-1/3 (100 pg/mI) the degradation of IL-6 mRNA was delayed
compared to unstimulated controls (Fig. 10). The calculated
half-life of IL-6 mRNA was extended from 2.8 hours in control
cells to 9.4 and 6.7 hours in HPMC exposed to IL-1/3 and PDE,
respectively. The combination of PDE+IL-1/3, however, resulted
in prolonged stabilization of IL-6 mRNA with levels remaining
constant over the 12 hours of the experiment.
Effect of cycloheximide
Pre-exposure of HPMC to cycloheximide resulted in 1.3-fold
and 2.2-fold increase in IL-6 mRNA expression (as measured by
IL-6/a-actin O.D. ratio) in response to IL-l/3 or PDE, respec-
tively. Moreover, cycloheximide promoted 5.4-fold increase in
IL-6 mRNA expression in control cells in the absence of addi-
tional stimulation. In contrast, cycloheximide did not appear to
increase the IL-6 mRNA expression in cells treated with
PDE+IL-1/3. In this case the IL-6/a-actin O.D. ratio was 0.79 and
0.75 for HPMC pre-exposed to cycloheximide and vehicle only,
respectively.
HPMC proliferation
Exposure of subconfiuent HPMC to PDE increased the cellular
incorporation of [3H]-thymidine in a time- and dose-dependent
manner. Following a 48-hour incubation the increase in [3H1-
thymidine incorporation was observed in HPMC exposed to PDE
dilutions as low as 1:128. The peak stimulation was achieved with
a 1:2 PDE dilution where [3H]-thymidine incorporation (cpm) was
2709 904 compared to 1029 368 in controls (N =6, z = 2.201,
P < 0.027). The addition of IL-1f3 did not modify the [3Hj-
thymidine incorporation into HPMC treated with either control
medium or PDE. In HPMC incubated with PDE (1:2) in the
presence of IL-i/I (1000 pg/mI) the incorporation was 2239 645
cpm (N = 6, z = 0.524, A(S).
Discussion
The demonstration that HPMC secrete IL-6 in vitro has led to
the suggestion that the increase in the intraperitoneal levels of
IL-6 occurring during peritonitis might be, at least in part, of
mesothelial origin [171. To assess the potential of the mesothelium
to contribute to this rise more precisely, in the present study we
800
600
400
200
0
0 .
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Fig. 6. Dose effect of IL-ira on IL-b generation
by HPMC exposed to PDE and IL-i /3. Growth
arrested HPMC were exposed to control
medium or PDE in the presence or absence of
IL-I/I (100 pg/mI), and simultaneously treated
with increasing concentrations of IL-ira (0.1 to
1000 nglml) for 24 hours. Data represent the
mean SEM of 5 experiments with HPMC
isolated from different omental specimens. *A
statistically significant difference compared to
untreated controls. Symbols are: () control;
(E:) IL-I /3; () PDE; (I) PDE + IL-1/3.
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Fig. 7. IL-h mRNA expression in HPMC treated with PDE and JL-1f3. Following timed exposure of growth arrested HPMC to control medium or PDE
in the presence or absence of IL-lp (100 pg/mI) total cellular RNA was extracted, reverse transcribed and PCR amplified for IL-6 and a-actin. PCR
products were separated by electrophoresis in ethidium bromide stained 3% agarose gels (A), and the results were presented as the densitometric ratios
of IL-6/a-actin (B). Symbols are: (A) PDE + IL-l13; () PDE; (•) IL-1; (LII) control.
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have investigated the induction of IL-6 synthesis in HPMC
exposed to peritoneal dialysis effluent.
Incubation of growth arrested HPMC in the presence of
four-hour spent dialysate pooled from infection-free CAPD pa-
tients resulted in a time- and dose-dependent increase in the
release of IL-6. PCR amplification of the reverse transcribed
HPMC RNA revealed that this increase was accompanied by the
induction of IL-6 mRNA. In this model the release of IL-6 in
response to PDE may represent the mesothelial fraction of low
IL-6 levels detected normally in drained dialysates from non-
infected CAPD patients.
To mimic the inflammatory state in vivo, PDE has further been
supplemented with IL-1/3 and TNFs, the potent pro-inflamma-
tory cytokines known to be present in the peritoneum during
initial stages of infection [4, 5, 9]. The effect of these cytokines on
the IL-6 release by HPMC in vitro has previously been well
established [17]. Both IL-Ip and TNFa have been shown to
induce expression of specific IL-6 mRNA and increase the
secretion of IL-6 from HPMC. Interestingly, however, the com-
bination of these cytokines produced only an additive release of
HPMC IL-fl, contrasting with the synergistic effects seen in many
systems tested [19, 25, 261. The present study demonstrates that in
Fig. 8. Representative competitive PCR standard
curve for a single extract of HPMC RNA. The
experimental HPMC RNA was reverse
transcribed and the constant amounts of sample
target eDNA were subjected to PCR
amplification in the presence of serial dilutions
of competitive DNA standard (IL-6 MIMIC).
PCR products were resolved on 3% agarose!
ethidium bromide gel (A). Following
densitometric scanning the IL-6/IL-6 MIMIC
O.D. ratio was plotted as a function of IL-6
MIMIC concentration and the amount of target
eDNA determined from the point in which the
ratio reached 1:1 (B). y = 0.225 log(x) + 0.931.
the environment of PDE the stimulatory action of IL-1p, and to
lesser extent TNFa, can be amplified in a synergistic fashion.
Combination of IL-1f3 together with PDE resulted in a synergistic
increase in IL-6 synthesis that was significantly greater than the
additive values of the two stimuli alone. This synergistic effect
appeared to depend on both the concentration of PDE and the
dose of cytokine, and occurred well within the range of IL-I 13
concentrations present in the peritoneal cavity during peritonitis
[4, 9].
The similar rise in HPMC IL-6 release was achieved when
recombinant cytokines were replaced with PM0-conditioned me-
dium. The supernatants from both control and S.epidermidis-
stimulated PMØ induced a synergistic increase in HPMC IL-fl
release when combined with PDE. Previous studies, utilizing
anti-cytokine antibodies and specific cytokine inhibitors, have
clearly identified that the stimulatory capacity of PM0-condi-
tioned media towards HPMC IL-fl, IL-8, and prostaglandin
synthesis was primarily related to their IL-1f3 and TNFa content
[27, 28]. Indeed, co-incubation of HPMC with IL-ira significantly
reduced the PDE+IL-l/3—stimulated IL-6 release, indicating that
IL-I /3 is a key mediator in the superinduction phenomenon. In
this respect Fieren et a! have demonstrated that PMØ harvested
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Fig. 9. Quantitation of !L-6 mRNA in HPMC exposed to PDE and IL-1/
Growth arrested HPMC were exposed to either control medium or PDE
in the presence or absence of IL-113 (100 pg/ml) for six hours. At this time
point total RNA was extracted, reverse transcribed and the cellular IL-6
mRNA concentration was assessed by competitive PCR. Data presented
are the mean SEM amount of IL-6 mRNA (fM/J.Lg of total extracted
RNA) in HPMC from 5 separate donors. *A statistically significant
difference in the amount of HPMC IL-6 mRNA compared to the control.
**A statistically significant synergistic difference in HPMC IL-6 mRNA
compared to the expected additive value for PDE and IL-1J3.
from CAPD patients during episodes of peritonitis display an
increased capacity to secrete IL-1f3 upon LPS stimulation [29].
Interestingly, IL-ira also appeared to be capable of decreasing the
constitutive IL-6 release, suggesting that this might in part be due
to the inhibition of endogenously secreted mesothelial IL-1f3 [30].
The synergistic IL-6 increase does not seem, however, to be
attributable to enhanced HPMC proliferation. Although PDE
stimulated [3H]-thymidine incorporation into HPMC, this effect
was not modified by the presence of IL-i/i.
Pre-treatment of HPMC with actinomycin D resulted in a
dose-dependent inhibition of PDE+IL-1f3—stimulated IL-6 re-
lease, indicating that this effect is regulated at the transcriptional
level. We demonstrated that HPMC responded to a combination
of PDE and IL-i/i by dramatically increasing IL-6 mRNA levels.
Quantitative analysis by competitive RT/PCR revealed the syner-
gistic nature of this increase, since the total amount of IL-6
mRNA generated under these conditions was significantly above
the predicted additive value.
The lL-6 gene expression in HPMC treated with a combination
of PDE and IL-i /3 appeared also to be regulated at the post-
transcriptional level as indicated by actinomycin D chase experi-
ments. The IL-6 mRNA transcript induced in response to
PDE+IL-1f3 was much more stable than that induced by either
PDE or IL-i/i alone. The mechanism underlying enhanced IL-6
mRNA stability may involve the inhibition of mRNA-destahilizing
proteins or cell-type specific processing of mRNA sequences
recognized by these proteins. Stabilization of mRNA is an effec-
tive mechanism for increasing the pooi of translatable mRNA and
ultimately the amount of protein synthesized. Thus the combina-
tion of increased gene transcription together with the prolonged
stability of the mRNA transcripts may account for the superin-
duction of IL-6 synthesis in HPMC exposed to PDE in the
presence of IL-I/I.
Transcriptional activation of IL-6 mRNA by PDE+IL-i/3 ap-
peared to be accomplished without the need for newly synthesized
protein intermediates, since pre-treatment of HPMC with cyclo-
heximide had no apparent effect on the PDE+IL-1/3—induced
IL-6 mRNA. In contrast, cycloheximide increased the expression
of IL-6 mRNA both in cells treated singly with PDE or IL-I/i and
also in unstimulated controls. Cycloheximide has previously been
shown to enhance IL-6 mRNA expression in some cell types [31]
presumably by inhibiting the synthesis of mRNA-destabilizing
proteins and/or transcriptional repressors. The complete stabili-
zation of steady-state IL-6 mRNA levels by the combination of
PDE together with IL-I/i might explain the inability of cyclohex-
imide to further augment the IL-6 mRNA expression. The more
precise characterization of the mechanisms governing the IL-6
gene expression in HPMC should clarify this issue. The transcrip-
tional control elements identified in the 5'-flanking region of the
IL-6 gene include glucocorticoid responsive element (GRE),
cAMP responsive element (CRE), serum responsive element
(SRE), and the NF-KB, NF-IL-6 and AP-i binding sites [32]. The
potential involvement of these elements in the PDE+ IL-i/i—
induced HPMC IL-6 gene expression is currently being investi-
gated.
The nature of the PDE stimulatory potential remains hypothet-
ical. Following a four-hour dwell the peritoneal dialysis effluent
contains a plethora of "uremic molecules" as well as a mixture of
different mediators of both systemic and local origin. Some of
these mediators, including LTB4, TNFa, TGF-/3, and IL-4, have
been shown to synergize with IL-i in the production of IL-6 in
other cell systems [25, 31, 33—36]. Whether the PDE-mediated
mesothelial IL-6 superinduction is related specifically to the local
activation within the peritoneum or related to the uremic state per
se remains to be determined.
The function of intraperitoneal IL-6 is unknown. IL-6 is a
pleiotropic cytokine involved in immune and inflammatory re-
sponses. Multiple actions of IL-6 include induction of B-lympho-
cyte differentiation and immunoglobulin production, activation
and differentiation of T-cells, and stimulation of hepatic synthesis
of acute phase proteins [37]. Increased levels of IL-6 have been
associated with several inflammatory conditions including septic
shock, rheumatoid arthritis, and meningitis [32]. IL-6 may also
exhibit anti-inflammatory properties since it is capable of sup-
pressing the expression of IL-i and TNFa [38, 39], and inducing
circulating IL-ira and soluble TNFp55 receptor [40]. This led to
the suggestion that the intraperitoneal IL-6 might act to control
rather than to amplify the inflammatory response [41]. The
demonstration that the peritoneal mesothelium is able to produce
massive amounts of IL-6 during peritonitis adds further evidence
to the belief that the mesothelial cell plays a central role in the
control of inflammation in the peritoneal cavity.
Reprint requests to Dr. Nicholas Topley, Institute of Nephrology, Cardiff
Royal Infirmaty, Newport Road, Cardifl CF2 ISZ Wales, United Kingdom.
E-mail: l00710.l025@compuserve.com
Appendix
Abbreviations are: CAPD, continuous ambulatory peritoneal dialysis;
HPMC, human peritoneal mesothelial cell; IL-i/I, interleukin-1/3; IL-ira,
interleukin-1 receptor antagonist; IL-6, interleukin-6; IL-8, interleukin-8;
PDE, peritoneal dialysis effluent; PMØ, peritoneal macrophage; PM0-
CM, peritoneal macrophage conditioned medium; S.epiPMø-CM, S.
epidinnidis-stimulated PMØ conditioned medium; RT/PCR, reverse tran-
scription/polymerase chain reaction; TNFa, tumor necrosis factor-a.
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Fig. 10. S/ability of IL-b rnRNA in HPMC treated with PDE and IL-I , Growth arrested HPMC were stimulated with either control medium or PDE
in the presence or absence of IL-1 (100 pg/mI) for six hours and then pulsed with 0.5 jrg/nil of actinomycin D (time zero). The rate of mRNA
degradation was determined by extracting total J-TPMC RNA at various times after the addition of actinomycin D, and performing RT/PCR. PCR
products were separated by flat bed electrophoresis in ethidium bromide stained 3% agarose gels (A). Following densitometric analysis the TL-6/a-actin
O.D. ratios were calculated and the results were expressed as a percentage of the value obtained at time zero (B). Symbols are: (A) PDE + IL-1; (S)
1L-1; () PDE; ([I]) control.
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